RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Understanding the axon-glial functional unit in myelination and remyelination' demonstrating excellence, impact and implementation quality for a Seventh Framework call.

assistant: **Abstract**

Loss or damage of myelin is one of the major mechanisms underlying the pathology of several neurological disorders, e.g. leukodystrophies, central and peripheral neuropathies, and inflammatory demyelinating diseases such as multiple sclerosis (MS), a serious health as well as economic and social burden at European level. Remyelination, the process by which demyelinated axons are reinvested with new myelin sheath, is required to ensure recovery of physiological activity of the nerves. Even if spontaneous remyelination in human demyelinating diseases can occur, it is an uneven process often insufficient to preserve axon integrity. Long-term axon protection could be achieved through the re-establishment of an efficient axon/myelin functional unit. Only a “correct” remyelination consisting in the preservation of the original axonal and myelin expressed proteome could potentially reduce axonal loss. No clear understanding of the key molecules involved in myelination and remyelination is at the moment available. Conventional molecular and cell biological assays do not provide a complete profile of the molecular changes involved in the establishment and maintenance of the myelin sheath. The fellow will apply a multidisciplinary approach. Forefront proteomics techniques (iTRAQ) will allow to profile the membrane proteins present at the axon/myelin interface and involved in initiating and maintaining myelination. The fellow will also address how remyelination, in a demyelinating animal model, differs from developmental myelination. The localization and specific function of a subset of interesting candidates will be analyzed in vitro and in vivo, in order to broaden our knowledge of the basic molecular processes underlying myelination/remyelination and to identify potential thera
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'B-2001-etc', explaining its relevance to EU policy priorities under Fifth Framework.

assistant: **Impact**

The current fundamental advances made in the study of Stable and Unstable Homotopy are spreading to some other activity areas of Mathematics and Physics, where they have been shown to be very successful tools at the cutting-edge of research.European Summer Schools held at the CRM since 1995 have addressed many of these advances, and they provided many of the actual European young researchers with their very first contact with the subject. Therefore, the aim of this PhD Euroconference (YECAT 2001) is to offer the opportunity to meet again European young researchers in algebraic topology, and show and know the latest advances on the subject. New viewpoints will make applications of their results to other areas possible. Within that spirit, a group of renowned European young researchers have been selected, fitting in the profile.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Neuron Soundware: detecting machine failures early combining sound, AI and IoT technologies' under Horizon Europe.

assistant: **Concept**

NSW is an AI-based acoustic and vibration diagnostic technology for early detection of broken machines and process monitoring, providing unparalleled insight into the operation of mechanical systems. Combined with its large-scale applicability and ease of use, it disrupts the way machines are diagnosed, facilitating industrial sustainability and catering to the needs of Industry 4.0. Our technology acts as an auditory cortex, understanding audio signals and detecting salient problems, delivering highly reliable results with 99.6% accuracy. NSW's integrated hardware with embedded edge software and cloud-based software platform automatically detects machine faults before other methods, preventing costly downtime and unnecessary maintenance. Our detection process utilizes our proprietary audio dataset, which contains terabytes of data and is continuously expanded with each new anomaly, improving the accuracy of the algorithms, the faults addressed and the types of machines.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Nano-fabrication with focused ion beams' under Fifth Framework.

assistant: **Concept**

Controlled and reproducible fabrication of nano-structured materials will constitute one of the main industrial challenges for the next ten years. To overcome severe limitations of existing nano-fabrication techniques, we plan to develop and improve an innovative technology, the Nano-fabrication with Focused Ion Beams (Nano-FIB). This Nano-FIB project will be conducted efficiently thanks to the complementary areas of expertise brought together in our consortium.Our project is the archetype of future intelligent instruments combining decisive and unique capabilities:1) Direct and clean nano-patterning processing below the 10 nm range.2) Self diagnostic and automatic repair capability.The performances and the economical impact of this technology will be validated through strategic applications.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'Redirecting Cytotoxic T Lymphocytes towards Leukemic antigens' goes beyond current state-of-the-art under Sixth Framework.

assistant: **Innovation**

We propose to make human T cells that bear chimeric receptors specific for CD33, a leukemia-associated antigen, and demonstrate that they are cytotoxic to human myeloid malignancies expressing this target antigen. However, the lack of stimulation through t he native T-cell immune receptor and the paucity of costimulatory molecules on the leukemia cells limit the survival, growth and functional activity of these chimeric effector cells once they are re-injected in vivo in patients. We plan to overcome this limitation by incorporating the CD33 chimeric receptor into cytotoxic T cells specific for EBV antigens (chimeric EBV-CTLs).EBV antigens are persistently expressed by B cells in vivo, together with high levels of costimulatory molecules. Hence, they may provide the native receptor and costimulatory signals needed to sustain and expand the modified effector cells for their subsequent interaction with leukemic cells through their chimeric CD33 receptor. We will test our hypothesis in three aims. In Aim 1, we will compare the in vitro cytotoxic activities of chimeric EBV-CTLs with those of unselected chimeric T cells from EBV-seropositive patients with advanced CD33+ myeloid malignancies against established myeloid leukemia cell lines or primary myeloid blasts. In Aim 2, we will enhance T-cell activation by introducing costimulatory elements into the signalling domain of chimeric receptors expressed on the T-cell surface. In Aim 3, we will evaluate the antileukemic activity of chimeric T cells against a human CD33+ AML in vivo in NOD-SCID mice. If effective, we will seek approval to initiate a phase I/II clinical trial of chimeric CTLs in EBV-seropositive patients with relapsed or high-risk CD33+ leukemia.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'INTELLIGENT COORDINATION OF OPERATION AND EMERGENCY CONTROL OF EU AND RUSSIAN POWER GRIDS' (ICOEUR).

assistant: **Concept**

The interstate integration of power grids provides multiple advantages concerning operation security, integration of renewable energy as well as energy trading. Due to this fact the UCTE interconnection expands continually since its establishment. Consideration is given to different scenarios of joint operation of UCTE and NORDEL with power grids on the territory of the former USSR. Due to the fact that such an interconnection is second to none in the World in terms of the scale and distance of the interconnection and number of countries involved, strong R&D and innovations are urgently required along with the recent development of technologies. Bulk power grids may encounter major blackouts, which originate in increasing complication in monitoring, operation and control of interconnected power grids as well as in limited knowledge of the total system state. Therefore the possible future interconnection between the European and Russian electricity transmission systems requires elaborating methods for monitoring, control and protection of large scale systems and especially for the support of their interconnections. The development and prototypically implementation of these new methods and tools is the major goal of the ICOEUR project. New technologies like Wide Area Monitoring, Control and Protection as well as advanced network controllers (FACTS) and HVDC systems will be considered. Envisioned ICOEUR goals can be achieved only in close cooperative work of experts, with extensive knowledge of EU and Russian power systems as well as manufacturers and network operators. The ICOEUR consortium involves leading experts in all these domains and guarantees efficient collaboration and knowledge required for testing the methodologies developed. The joint development of innovative
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Gene Editing as Therapeutic Strategy for C9ORF72 Linked ALS/FTD' (CORFEDITING).

assistant: **Innovation**

Expansion of a hexanucleotide repeat G4C2 in the non-coding region of chromosome 9 open reading frame 72 (C9orf72) is the most common genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS is a fatal condition characterized by progressive motor deficits, degeneration of upper and lower motor neurons (MNs) and death from neuromuscular respiratory failure in the majority of afflicted individuals within 3-5 years. Currently, the economic burden of care and treatment for patients with ALS/FTD is expensive and continues to significantly rise in Europe and worldwide. While significant genetic discoveries have been made in the field, they have not yet translated to treatment options for patients with ALS and FTD. Thus, research efforts aimed at identifying therapeutic targets are of the utmost importance to enable therapeutic development for these devastating disorders. In this ERC Proof of Concept project, we will design, optimise and test gene therapy vectors containing CRISPR/Cas9 system to selectively remove the pathogenic ALS/FTD-related C9orf72 hexanucleotide repeat expansion in mouse models of C9orf72-related ALS, with the ultimate aim of designing a therapy for patients with C9orf72-related ALS/FTD. The ultimate benefit of this approach goes far beyond just ALS/FTD however. A successful CNS gene therapy for C9orf72 related disease potentiates the prospect of developing similar approaches to treat multiple disease scenarios amenable to gene modification. Indeed, growing evidence suggests that C9orf72 repeat expansions also contribute to a wide spectrum of neurodegenerative diseases such as Alzheimer’s, Huntington’s, multiple sclerosis, Parkinson’s disease and cerebellar ataxias. We therefore anticipate that our strategy could be ben
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'A beating Heart-on-Chip for pre-clinical early detection of drugs cardiac safety', explaining its relevance to EU policy priorities under Horizon 2020.

assistant: **Impact**

The cost to develop new drugs is huge, mainly due to the failure rate in the drug discovery process. Current in vitro modelsare too simplistic, owing to limited prediction of systemic side-effects of molecules, e.g. cardiotoxicity. On the other hand, invivo models, far more complex, provide responses to drugs often different from those found in humans.Furthermore, recent legislation about 3R principle (i.e. Directive 2010/63/EU) is encouraging Pharma industry towards thesearch for methods alternative to animal testing. In this scenario, the demand for innovative in vitro tools able to predictcardiotoxicity already in the pre-clinical phase is urgent. To address this need BiomimX is developing uHeart. uHeart is aminiaturized model of human heart, responding to drugs likewise the natural heart. Our patented technologies allow thegeneration of fully-mature cardiac tissues, providing 3D cardiac cells with a mechanical training resembling the heartbeating. uHeart is the only tool currently available featuring such a high level of specificity in replicating heart responses, andthanks to its micrometer scale it comes with a huge saving in terms of costs and analysis time. BiomimX is currentlyvalidating uHeart as a predictor of cardiac drug safety in early stages of the pre-clinical phase. BiomimX targets the marketof Pharma and CRO that will use uHeart as innovative tool to screen the cardiotoxicity of putative new molecules, savingtime and money for drug development. Thanks to this innovation project, BiomimX will complete both technical and freedomto operate analyses for uHeart. In the meanwhile, a roll-out phase will be carried out with ten potential customers. At the endof Phase I, uHeart is expected to reach a TRL7. A refined business plan will allow BiomimX to negotiate
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Horizon 2020 proposal for the project 'PREeclampsia risk stratification test: development of a suitable CALIbration framework for the analysis of a multiplex panel of endogenous compounds by LC-MS'.

assistant: **Objectives**

PREeclampsia risk stratification test: development of CALIbration framework for the analysis of a multiplex panel of endogenous Compounds by LC-MS. Metabolomic Diagnostics (MDx)  is an innovative company which is developing tests for pre-eclampsia in pregnancy.  MDx consists of a team of scientists and entrepreneurs with clinical support. The enterprise and the experienced researcher propose to combine their expertise to support the development of a robust test for the risk stratification of preeclampsia. One of the key challenges in the product development is establishing the optimal way to perform the quantification of the metabolite targets underpinning the preeclmapsia test.  In the case of risk stratification products, the predictive metabolite biomarker profiles are merely a perturbation in the levels of a set of endogenous occurring metabolites. As a result, the internationally well-established LC-MS test validation framework as known for bioanalysis is not readily applicable.The researcher’s doctoral dissertation focused on the development and subsequent validation of novel mass spectrometric assays for endogenous metabolites and she explored a novel validation strategy to overcome the limitations of the classic bioanalysis validation framework with regards to validation mass spectrometric assays for endogenous compounds.   It would be difficult for MDx to find a candidate with a more relevant background for this project and it would be equally difficult for  the researcher to find a company in Europe with such a perfect project to implement her expertise extensively.The scope of this project is the development of an appropriate quantification strategy for the product, with the following prerequisites:-1. Delivering robust quantification data which can be fed to
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'European network on brain dysmyelinating diseases:diagnostic, molecular and therapeutic approach' to be submitted under Fourth Framework.

assistant: **Abstract**

To identify clinically homogenous groups of patients affected by dysmyelinating diseases.To search new biochemical diagnostic markers of dysmyelinogenesis process.To identify molecular defects involved in X-linked and recessive forms of dysmyelinating diseases.To test on X-linked dysmyelinated mutant mice different strategies for CNS myelin repair.This European network will be developed by 4 different approaches: The clinical approach will include 11 different neuropediatric European centers, with the aim to identify clinically homogeneous groups of patients affected by a dysmyelinating process among hereditary spastic paraplegia, ataxia, nystagmus, or leucodystrophies without etiology using a prospective study.New diagnostic markers of the dysmyelinogenesis process will be searched using nuclear magnetic resonance (NMR) imaging and proton NMR spectroscopy coupled with capillary electrophoresis in dysmyelinating mutant mice and affected patients.The molecular biology approach will include: (1) fundamental studies on CNS myelin proteins (proteolipoproteins (PLP), myelin olygodendrocyte glycoprotein), (2) analysis of transgenic mice mutated in different myelin protein genes (PLP, M6B), (3) studies on patients affected by brain dysmyelinating diseases by testing involvement of brain myelin protein genes.Different strategies for brain myelin repair will be tested in X-linked PLP mutant mice mimicking the different phenotypes observed in human, using combined gene and cell therapy with transplantation of myelin-forming cells.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'Biointegrable soft actuators alimented by metabolic energy' (INTEGRATE), addressing dissemination and exploitation.

assistant: **Impact**

State-of-the art implantable actuating devices, such as automated prosthetics, have time-limited operational capacities because they are sustained by batteries which, ultimately, rely on external power sources to be recharged. INTEGRATE proposes a radically new way to solve this problem: use metabolic energy from the patient to power implanted devices. To achieve this ambitious goal, INTEGRATE will develop i) new 3D printable soft actuating materials inspired by human muscles whit high performances and low power consumption and ii) an artificial organ capable of harvesting metabolic (biochemical) energy and transform it into electricity. The actuating materials (Bionic Muscles) will be prepared via self-assembly of  biocompatible colloidal liquid crystals and stimuli-responsive polymers. A modular design and 3D printability will offer the possibility to manufacture these materials on the basis of patient’s anatomy and needs. The Energy-Harvesting Organ will be capable of converting pH differences within various body fluids (e.g. gastric juice and saliva) in electricity with high efficiency, providing the necessary power to sustain the Bionic Muscles. This research will revolutionize the field of implantable devices and will represent a turning point in robotics, wearable technologies, materials science, energy conversion, and materials engineering.


**Keywords:** artificial muscles, bionics, energy-autonomous prosthetics